REMIX is a three-years project funded by INFN-CSN5 in 2021, with the goal of finding possible 47Sc and medical Terbium isotopes (149Tb, 152Tb, 155Tb and 161Tb) production routes by using accelerators. All the radionuclides of interest in the REMIX project, except for the therapeutic 161Tb, can be used to obtain theranostic radiopharmaceuticals, since they emit radiation suitable for both therapeutic and diagnostic purposes, as shown in Table 1 [1]. The study of the possible production routes is important since until now the limiting factor for clinical and preclinical studies with 47Sc-labeled radiopharmaceuticals is the lack of 47Sc availability. Studies to find the best proton-induced nuclear reaction that allows enough 47Sc production must also consider the simultaneous minimization of the coproduction of all possible contaminants. Particular attention must be paid to the other Sc-isotopes since they cannot be chemically separated from the produced 47Sc. Among the Sc-isotopes, the most critical is the 46Sc (83.79 d) as it has a longer half-life than the 47Sc (3.3492 d). As already reported, 47Sc was first studied in the PASTA project [2, 3, 4, 5] and the goal of REMIX is to measure the protoninduced nuclear reactions by using isotopically enriched 49Ti [6,7] and 50Ti targets. The enriched powders, purchased during 2018, were not suitable for target manufacturing with the HIVIPP technique, as previously described. For this reason, during 2019 and 2021 a cryomilling procedure was studied and optimized using the cheaper natTi metallic sponges to mimic the process and obtain metallic powders suitable for the HIVIPP deposition. During 2021, the first enriched 49Ti targets were realized [8,9] and characterized with IBA (Ion Beam Analysis) methods, exploiting the AN2000 accelerator at the LNL (HIX project, PI: S. Cisternino). On the other hand, the medical relevant Tb-isotopes have not been studied at the LNL during 2021 but are under investigation within the REMIX project [10].

The REMIX Project: Research on the Emerging Medical radIonuclides from the X-sections

P. Martini;A. Boschi;A. Duatti;
2022

Abstract

REMIX is a three-years project funded by INFN-CSN5 in 2021, with the goal of finding possible 47Sc and medical Terbium isotopes (149Tb, 152Tb, 155Tb and 161Tb) production routes by using accelerators. All the radionuclides of interest in the REMIX project, except for the therapeutic 161Tb, can be used to obtain theranostic radiopharmaceuticals, since they emit radiation suitable for both therapeutic and diagnostic purposes, as shown in Table 1 [1]. The study of the possible production routes is important since until now the limiting factor for clinical and preclinical studies with 47Sc-labeled radiopharmaceuticals is the lack of 47Sc availability. Studies to find the best proton-induced nuclear reaction that allows enough 47Sc production must also consider the simultaneous minimization of the coproduction of all possible contaminants. Particular attention must be paid to the other Sc-isotopes since they cannot be chemically separated from the produced 47Sc. Among the Sc-isotopes, the most critical is the 46Sc (83.79 d) as it has a longer half-life than the 47Sc (3.3492 d). As already reported, 47Sc was first studied in the PASTA project [2, 3, 4, 5] and the goal of REMIX is to measure the protoninduced nuclear reactions by using isotopically enriched 49Ti [6,7] and 50Ti targets. The enriched powders, purchased during 2018, were not suitable for target manufacturing with the HIVIPP technique, as previously described. For this reason, during 2019 and 2021 a cryomilling procedure was studied and optimized using the cheaper natTi metallic sponges to mimic the process and obtain metallic powders suitable for the HIVIPP deposition. During 2021, the first enriched 49Ti targets were realized [8,9] and characterized with IBA (Ion Beam Analysis) methods, exploiting the AN2000 accelerator at the LNL (HIX project, PI: S. Cisternino). On the other hand, the medical relevant Tb-isotopes have not been studied at the LNL during 2021 but are under investigation within the REMIX project [10].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2501732
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact